Sarepta (SRPT) PT Raised to $47 at Needham & Company; Sees Upside to $60
- Wall St. slips on President Trump's protectionist views
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative - Bloomberg
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- Qualcomm (QCOM) Thrashed as Apple (AAPL) Lawsuit Threatens Licensing Business Model
- McDonald's (MCD) Tops Q4 EPS by 3c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Needham & Company analyst Chad Messer raised his price target on Buy-rated Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $26.00), with upside to $60. Messer said "while we view the departure of FDA reviewer Dr. Ron Farkas as a potential positive for eteplirsen approval, we still believe the requested Western blot data from PROMOVI remains the critical deciding factor."
He added, "As a reminder, Western blot data from the original eteplirsen studies indicated an average increase of dystrophin of ~0.9%, which many FDA and Advisory Committee members found disappointing. However, there were issues with the way the blots were analyzed and a poor correlation between the original and a second analysis. We believe other evidence, such as a demonstration of consistent dystophin mRNA increases, support eteplirsen's mechanism and therefore are inclined to believe the PROMOVI samples will support approval."
They believe approval would justify a $3B+ market cap, or ~$60/share.
Shares of Sarepta Therapeutic closed at $25.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Upgrades Columbus McKinnon (CMCO) to Buy
- UPDATE: CLSA Downgrades Qualcomm (QCOM) to Underperform
- Seaport Global Securities Downgrades FMC Corp. (FMC) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA, Hot FDA News
Related EntitiesNeedham & Company, AdCom
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!